Volume | 685,324 |
|
|||||
News | - | ||||||
Day High | 0.6341 | Low High |
|||||
Day Low | 0.6075 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Citius Pharmaceuticals Inc | CTXR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.62 | 0.6075 | 0.6341 | 0.6256 | 0.6276 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,799 | 685,324 | $ 0.6186768 | $ 423,994 | - | 0.60 - 1.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:36:11 | formt | 100 | $ 0.6256 | USD |
Citius Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.64M | 159.09M | - | 0 | -33.69M | -0.21 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Citius Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTXR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.6251 | 0.6599 | 0.601 | 0.626506 | 755,739 | 0.0005 | 0.08% |
1 Month | 0.67 | 0.95 | 0.601 | 0.6971441 | 2,307,411 | -0.0444 | -6.63% |
3 Months | 0.741 | 1.07 | 0.601 | 0.7396162 | 1,573,830 | -0.1154 | -15.57% |
6 Months | 0.7811 | 1.07 | 0.60 | 0.7362821 | 1,077,303 | -0.1555 | -19.91% |
1 Year | 1.27 | 1.40 | 0.60 | 0.8695866 | 1,057,239 | -0.6444 | -50.74% |
3 Years | 2.62 | 4.56 | 0.60 | 1.86 | 1,794,160 | -1.99 | -76.12% |
5 Years | 1.14 | 4.56 | 0.40 | 1.80 | 2,295,511 | -0.5144 | -45.12% |
Citius Pharmaceuticals Description
Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |